Understanding how specific proteins affect leukemia in children
Epigenetic regulators define a dynamic chromatin landscape in NUP98-rearranged leukemia
['FUNDING_CAREER'] · DANA-FARBER CANCER INST · NIH-11061333
This study is looking at how certain proteins linked to leukemia in kids affect cancer growth, and it hopes to find new ways to treat young patients by seeing what happens when these proteins are removed.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DANA-FARBER CANCER INST (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11061333 on ClinicalTrials.gov |
What this research studies
This research investigates the role of NUP98-fusion proteins in acute myeloid leukemia (AML), particularly in children. It aims to understand how these proteins interact with chromatin modifying enzymes to drive cancer progression. By using a novel mouse model, researchers will explore the immediate effects of degrading these fusion proteins on gene expression and chromatin structure. The goal is to identify potential therapeutic targets that could improve treatment outcomes for young patients with NUP98-rearranged leukemia.
Who could benefit from this research
Good fit: Ideal candidates for this research are children aged 0-11 years diagnosed with acute myeloid leukemia, particularly those with NUP98 rearrangements.
Not a fit: Patients with other types of leukemia or those outside the specified age range may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies that improve survival rates for children with specific types of leukemia.
How similar studies have performed: Previous research has shown promising results in targeting chromatin interactions in leukemia, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
BOSTON, UNITED STATES
- DANA-FARBER CANCER INST — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HEIKAMP, EMILY — DANA-FARBER CANCER INST
- Study coordinator: HEIKAMP, EMILY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.